Skip to content

Dexmeditomidine as adjuvant to anesthesia

The Impact of ADRA2A and CYP2A6 Gene Polymorphism on sedative and analgesic effect of Dexmedetomidine

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230824059251N1
Enrollment
300
Registered
2023-09-01
Start date
2023-09-10
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraoperative sedation and analgesia. Thr drug under study will be given as adjuvant to anesthesia to produce sedation and analgesia and reduce the dose of anesthetic agents, analgesic and drugs for neasea & vomiting.

Interventions

Intervention group: intervention Group will be administered 1µg/kg dexmedetomidine hydrochloride intravenously over 10 min as a bolus just before the induction in addition to the standard anaesthes

Sponsors

Islamic International Medical College and Wah medical college
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ASA I &II Pakistani origin

Exclusion criteria

Exclusion criteria: No co-morbidity Non pregnant females

Design outcomes

Primary

MeasureTime frame
Intraoperative sedation and analgesia. Timepoint: beore interventiona and at 1/2 an hour interval and at 2hrs interval. Method of measurement: Ramsay Sedation scale, Visual analogue scale and polymorphism in genes.;Genotyping and Polymorphism in Receptor gene and in enzyme gene. Timepoint: Polymorphism cam be studies both in control and study group in blood sample of 2hsr interval. Method of measurement: Drug concentration will be meausred at 30 min and at 2hrs interval in both groups.

Countries

Pakistan

Contacts

Public ContactBrig (R) Dr Akbar Waheed

Islamic International Medical College and Wah medical college

akbar.waheed@riphah.edu.pk+92 51 9094111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 5, 2026